

Title (en)
NOVEL PYRAZOLE ANALOGS ACTING ON CANNABINOID RECEPTORS

Title (de)
NEUE, AUF CANNABINOIDREZEPTOREN WIRKENDE PYRAZOLANALOGA

Title (fr)
NOUVEAUX ANALOGUES DE PYRAZOLE AGISSANT SUR LES RECEPTEURS CANNABINOIDES

Publication
EP 1421077 A4 20041117 (EN)

Application
EP 02768751 A 20020829

Priority
• US 0227644 W 20020829
• US 31651501 P 20010831

Abstract (en)
[origin: WO03020217A2] One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the GB 1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.

IPC 1-7
C07D 401/12; C07D 231/14; C07D 401/10; A61K 31/415; A61P 29/00

IPC 8 full level
C07D 231/14 (2006.01); **A61K 31/415** (2006.01); **A61K 31/454** (2006.01); **A61K 31/4545** (2006.01); **A61P 1/08** (2006.01); **A61P 3/04** (2006.01); **A61P 25/00** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01); **A61P 25/32** (2006.01); **A61P 25/34** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 231/12** (2006.01); **C07D 233/54** (2006.01); **C07D 233/90** (2006.01); **C07D 401/10** (2006.01); **C07D 401/14** (2006.01); **C07D 403/10** (2006.01); **C07D 409/10** (2006.01); **C07F 7/22** (2006.01)

CPC (source: EP)
A61P 1/08 (2017.12); **A61P 3/04** (2017.12); **A61P 25/00** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 25/30** (2017.12); **A61P 25/32** (2017.12); **A61P 25/34** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07D 231/12** (2013.01); **C07D 233/64** (2013.01); **C07D 233/90** (2013.01); **C07D 401/10** (2013.01); **C07D 401/14** (2013.01); **C07D 403/10** (2013.01); **C07D 409/10** (2013.01)

Citation (search report)
• [X] WO 9721682 A1 19970619 - SANOFI SA [FR], et al
• [X] EP 0576357 A1 19931229 - SANOFI ELF [FR]
• [X] WO 0158869 A2 20010816 - BRISTOL MYERS SQUIBB CO [US], et al
• [A] US 5939429 A 19990817 - KUNOS GEORGE [US], et al
• [X] J P. MESCHLER ET AL.: "inverse agonist properties of n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide hcl(sr141716a)", BIOCHEMICAL PHARMACOLOGY, vol. 60, no. 9, 2000, NL, pages 1315 - 23, XP002295771
• [X] OMAR JBILO ET AL.: "stimulation of periferal cannabinoid receptor cb2", FEBS LETTERS, vol. 448, no. 21848, 1999, EU, pages 273 - 7, XP002295772
• [X] L. QUERE ET AL.: "structural requirements of non-peptide neurotensin receptor antagonists.", JOURNAL OF THE CHEMICAL SOCIETY, SECTION B: PHYSICAL ORGANIC CHEMISTRY., 1996, GB/CHEMICAL SOCIETY. LETCHWORTH., pages 2639 - 46, XP002295773
• [X] G. GRIFFIN ET AL.: "evaluation of the cannabinoid CB2receptor-selective antagonist,SR144528:", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 377, 1999, NL, pages 117 - 25, XP002295774
• See references of WO 03020217A2

Citation (examination)
RINALDI-CARMONA, M. ET AL.: "Biochemical and Pharmacological Characterisation of SR141716A, ...", LIFE SCIENCES, vol. 56, no. 23/24, 1995, pages 1941 - 1947, XP002044761

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)
WO 03020217 A2 20030313; WO 03020217 A3 20030821; AU 2002331766 A1 20030318; CA 2457922 A1 20030313; EP 1421077 A2 20040526; EP 1421077 A4 20041117; JP 2005507875 A 20050324

DOCDB simple family (application)
US 0227644 W 20020829; AU 2002331766 A 20020829; CA 2457922 A 20020829; EP 02768751 A 20020829; JP 2003524531 A 20020829